ChemicalBook > Product Catalog >API >Hormones and the Endocrine System >Others >Octreotide

Octreotide

Octreotide Suppliers list
Company Name: Hangzhou Peptide Biochem Co.,Ltd  Gold
Tel:86-0571-89197072,18668118770
Email:linda@peptide-manufacturer.com
Products Intro:Product Name:Octreotide Acetate
CAS:79517-01-4
Purity:98.50% Package:1g/bottle, 10g/bottle, 50g/bottle or at custoMer requireMent Remarks:USP,EP
Company Name: Cellmano Biotech Limited  Gold
Tel:+86-551-65326643
Email:info@cellmano.com
Products Intro:Product Name:Octreotide Acetate
CAS:79517-01-4
Purity:98% HPLC Package:5Mg;10Mg;1g
Company Name: Shanghai Boyle Chemical Co., Ltd.  
Tel:86-21-50180596
Email:sales@boylechem.com
Products Intro:Product Name:Octreotide
CAS:79517-01-4
Company Name: J & K SCIENTIFIC LTD.  
Tel:400-666-7788 +86-10-82848833
Email:jkinfo@jkchemical.com;market6@jkchemical.com
Products Intro:Product Name:Octreotide Acetate
CAS:79517-01-4
Package:100Mg,10Mg,500Mg
Company Name: 3B Pharmachem (Wuhan) International Co.,Ltd.  
Tel:86-21-50328103 * 801、802、803、804 Mobile:18930552037
Email:3bsc@sina.com
Products Intro:Product Name:Octreotide
CAS:79517-01-4
Purity:99% HPLC Package:1Mg ; 5Mg;10Mg ;100Mg;250Mg ;500Mg ;1g;2.5g ;5g ;10g
Octreotide Basic information
Digestive system drugs Dosage and administration Category Toxicity grading Acute toxicity Flammability hazard characteristics storage properties Extinguishing media
Product Name:Octreotide
Synonyms:SANDOSTATIN;SMS-201-995;[r-(r*,r*)]-d-phenylalanyl-l-cysteinyl-l-phenylalanyl-d-tryptophyl-l-lysyl-l-threonyl-n-[2-hydroxy-1-(hydroxy-methyl)propyl]-cysteinamide cyclic(2->7)-disulfide;OCTREOTIDE;OCTREOTIDE (SMS 201-995), ACETATE;cyclic(2-7)-disulfide,(r-l-threonyl-n-(2-hydroxy-1-(hydroxymethyl)propyl);d-phenylalanyl-l-cysteinyl-l-phenylalanyl-d-tryptophyl-l-lysyl-l-cysteinamid;r*))-(racetate(salt)
CAS:79517-01-4
MF:C49H66N10O10S2
MW:1019.24
EINECS:
Product Categories:Amino Acid Derivatives;Intermediates & Fine Chemicals;Peptides;Pharmaceuticals;Somatostatin receptor;peptide
Mol File:79517-01-4.mol
Octreotide Structure
Octreotide Chemical Properties
Melting point 153-156°C
storage temp. −20°C
solubility H2O: soluble
Safety Information
WGK Germany 3
MSDS Information
ProviderLanguage
SigmaAldrich English
Octreotide Usage And Synthesis
Digestive system drugsOctreotide belongs to digestive system drugs, which is an artificially synthetic cyclic octapeptide compound, and is a homolog of natural somatostatin. It contains the pharmacological activity of a natural somatostatin, and has long-lasting effects (the half-lifetime of this product is 1.5-hour, while it is 2 to 3 minutes of natural somatostatin). The product selectively inhibited the secretion of growth hormone, glucagon and insulin, and the effect is stronger than natural. It is proved by animal experiments: intravenous this product for 15 minutes, the inhibition of growth hormone release is 70 times higher than the natural somatostatin, and the inhibition of insulin release is 3 times than the natural somatostatin. It has also the inhibition effect to thyrotropin, adrenocorticotropic hormone, gastrin, cholecystokinin, vasoactive intestinal polypeptide. As well as it can inhibit the secretion of gastric acid, pancreatic amylase, lipase and pepsin. It can slow down pass through time of gastrointestinal tract, which promotes the absorption of water and electrolytes. It has the contract effect of visceral blood vessels, which can reduce splanchnic blood flow, and reduce the blood flow of liver. Thus, it reduces the portal pressure and portal blood flow, and reduces excessive secretion of intestinal tract, and it may enhance the intestinal absorption of water and the Na+.
The amino acids of 1,4,8 positon is unnatural amino acids on the chemical structure of the product, so it is less susceptible to enzyme hydrolysis, and it has more longer half-lifetime. It is absorbed rapidly and completely by subcutaneous injection of the product. The time to peak plasma concentration is 0.5-hour, and the volume of distribution is 0.27 L/kg. The half-lifetime is 1.5-hour, and the metabolic clearance rate is 160 ml/min. It is biphasic elimination as intravenous injection of this product, the half-lifetime of α phase and β phase are 10 minutes and 90 minutes, respectively. The plasma protein binding rate is 65%.
Octreotide is clinically used for the treatment of esophageal varices caused by portal hypertension, acromegaly, gastrointestinal bleeding including cirrhosis, esophageal varices bleeding, peptic ulcer bleeding and stress ulcer bleeding, pancreatic diseases including heavy acute pancreatitis, pancreatic trauma, or pancreatic fistula after surgery, and prevention of complications after pancreas surgery. It is also used for gastrointestinal fistula, digestive endocrine tumors such as vasoactive intestinal peptide tumors, gastrinoma, glucagon tumors, ectopic ACTH syndrome, carcinoid syndrome, and it is used for acromegaly, exophthalmus hyperthyroidism disease, after the removal of the entire colon appearing persistent and intractable diarrhea, AIDS-related diarrhea. Intrathecal injection of this product can treat cancer pain.
Dosage and administration1. prevention of complications of pancreatic surgery: one hour before surgery, subcutaneous injection of 0.1mg octreotide; then 0.1mg subcutaneously 3 times a day for seven days.
2. treatment of varices caused by esophagus portal hypertension: 0.1mg intravenous injection, then 0.5mg, every two hours by intravenous drip.
3. stress ulcers and gastrointestinal bleeding: 0.1mg subcutaneously 3 times a day.
4. severe pancreatitis: 0.1mg subcutaneous injection, 4 times a day for 3 to 7 days; pancreatic injury or pancreatic fistula after surgery, subcutaneous injection, each 0.1mg, every 8 hours for 7 to 14 days.
5. gastrointestinal fistula and digestive tract endocrine system of cancer adjuvant therapy: subcutaneous 0.1mg, 3 times a day, a course for10 to 14 days.
6. digestive system endocrine tumors, Graves' disease, acromegaly and AIDS-related diarrhea: subcutaneous 0.1mg, 3 times a day, acromegaly treatment for 10 to 14 days. There are injection site pain or tingling, and it is usually ease after 15 minutes.
Gastrointestinal adverse reactions include anorexia, nausea, vomiting, diarrhea, abdominal cramps. Occasionally it will appear hyperglycemia, cholelithiasis, abnormal glucose tolerance, and liver function abnormalities (γ-glutamyl transferase increased and transaminase slightly increased) and others. Patients with dysfunction of kidney and pancreatic, and cholelithiasis should be used with caution. Pregnant women, lactating women and children are prohibition.
The above information is edited by the chemicalbook of Kui Ming.
Categorytoxic substances
Toxicity gradinghighly toxic
Acute toxicityintravenous-rat LD50: 18.1 mg/kg; intravenous-mouse LD50: 72.3 mg/kg
Flammability hazard characteristicscombustible; fire decomposition of toxic nitrogen oxide compounds, sulfur oxide fumes
storage propertiescold warehouse, ventilated and dry; and separately stored with food raw materials
Extinguishing mediawater, carbon dioxide, dry power, sandy soil
Chemical PropertiesColourless to off-white lyophilised solid
UsesOctapeptide analog of Somatostatin. A gastric antisecretory agent. Used in treatment of acromegaly
Usesnatural hormone somatostatin
Octreotide Preparation Products And Raw materials
Preparation ProductsOctreotide acetate
Tag:Octreotide(79517-01-4) Related Product Information
DOTA-[TYR3]-OCTREOTIDE ACID octreotide, TETA-Phe(1)- technetium Tc 99m-tricine-hydrazinonicotinyl-Phe(1)-Tyr(3)-octreotide technetium Tc 99m hydrazinonicotinyl-Tyr(3)-octreotide DTPA-octreotide 3-Tyr-octreotide,[Tyr3]-octreotide, [Tyr3]-SMS 201-995,[Tyr3]-Octreotide desferrioxamine B-succinyl-phenylalanine(1)-octreotide technetium Tc 99m 6-(4-thioureabenzyl)-3,3,9,9-tetramethyl-4,8-diazaundecane-phenylalanine(1)-octreotide DTPA-benzyl-acetamido-D-Phe(1),Tyr(3)-octreotide (DOTA(0)-Phe(1)-Tyr(3))octreotide octreotide, DOTA-Phe(1)- Octreotide Acid (Octreotate) DOTA-(TYR3,THR8)-OCTREOTIDE ACETATE,DOTA-[Tyr3]-Octreotate, DOTA-[Tyr3, Thr8]-Octreotide, DOTA-TATE [DOTA-DPHE1, TYR3]OCTREOTIDE,DOTA-[TYR3]-OCTREOTIDE ([125I]-TYR0)-OCTREOTIDE OCTREOTIDE ACID SDZ CO 611 Octreotide